Inuvair Nexthaler

Formoterol fumarate / beclometasone dipropionate, the active ingredient in Inuvair Nexthaler, is a combination inhaled corticosteroid (ICS) and long‑acting β2‑agonist (LABA) presented as an unspecified strength dry powder inhaler for inhalation use. It treats asthma and chronic obstructive pulmonary disease (COPD) in adults and adolescents.

GNH USA supplies Inuvair Nexthaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Inuvair Nexthaler is a combination inhaler used for maintenance therapy in obstructive airway diseases.

Asthma: improves control of symptoms and reduces the frequency of exacerbations. COPD: provides long‑term bronchodilation and anti‑inflammatory effect to lessen breathlessness. Maintenance therapy: enhances lung function and decreases the need for rescue medication.

Inhaled therapy may cause a range of adverse reactions.

Common Side Effects: - Throat irritation or soreness. - Hoarseness or voice changes. - Cough after inhalation. - Oral candidiasis (thrush). - Headache. - Tremor.

Serious or Rare Side Effects: - Paradoxical bronchospasm. - Severe allergic reaction (anaphylaxis). - Adrenal suppression with prolonged use. - Pneumonia, especially in COPD patients. - Cardiac arrhythmias. - Hyperglycaemia in susceptible individuals.

Use of Inuvair Nexthaler requires careful monitoring and patient education. - Inhaler technique: ensure correct device handling to achieve optimal drug delivery. - Monitor for signs of infection: especially respiratory infections in COPD. - Mouth rinsing: advise patients to rinse after each dose to reduce oral candidiasis. - Avoid abrupt discontinuation: taper under medical supervision if long‑term therapy is stopped. - Store at room temperature below 25°C: keep in the original pack, protect from moisture.

Inhaled corticosteroid/LABA combinations can interact with several drug classes.

Major Interactions (Avoid): - Beta‑blockers: may blunt bronchodilator response and worsen asthma/COPD. - MAO inhibitors: increase risk of cardiovascular events when combined with LABA. - Diuretics: may potentiate hypokalaemia caused by β2‑agonist activity.

Moderate Interactions (Monitor Closely): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise systemic corticosteroid exposure. - Theophylline: concurrent use can increase the risk of tremor and tachycardia. - Live vaccines: immunosuppressive effect of corticosteroid may reduce vaccine efficacy.